



Alpa Laboratories Ltd.

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91 731-429 4567 Fax No. : +91 730-429 4444

Email : mktgdom@alpalabs.in

CIN : L85195MP1988PLC004446

29th July, 2026

To,
Listing Department,
BSE Limited.
Rotunda Building, P J Towers
Dalal Street, Fort,
Mumbai – 400 001
Scrip Code: 532878

To,
Listing Department,
National Stock Exchange of India Limited.
'Exchange Plaza', C-1, Block G,
Bandra - Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: ALPA

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that the Company has accorded approval in principle for exploring the proposed promotion and incorporation of an overseas company in the Federal Republic of Nigeria under the proposed name "Alpa Biopharm Limited" (or such other name as may be approved by the competent authority), in association with Blueseal Pharmaceuticals Limited, Nigeria, subject to applicable statutory, regulatory and other necessary approvals, wherever required.

The proposed entity, if incorporated, is intended to undertake pharmaceutical and healthcare-related business activities. The proposed shareholding, capital contribution, investment, governance structure and other terms, if any, shall be considered separately in accordance with the applicable laws and necessary approvals.

This disclosure is being made at the stage of approval in principle only. The proposed company has not been incorporated as on the date of this disclosure, and no investment has been made by the Company. Appropriate disclosures, if required, shall be made upon the occurrence of any material event.

You are requested to take the same on records.

For ALPA LABORATORIES LIMITED

Mahendra
MAHENDRA SINGH CHAWLA
DIRECTOR
DIN 00362058

